Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 7/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | SCN1A | P35498 | 1/20 | 0.42 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.41 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3063629 | 0.83 | KDM4E (0.48) | TLR8KCNH2KDM4ELMNACYP1A2 | |
| SCHEMBL12737723 | 0.80 | KDM4E (0.50) | TLR8KDM4ECYP1A2TDP1MAPT | |
| SCHEMBL3071109 | 0.77 | ALDH1A1 (0.50) | TLR8KDM4ELMNACYP1A2TDP1 | |
| SCHEMBL3079638 | 0.77 | KDM4E (0.43) | TLR8KDM4ELMNACYP1A2CYP2D6 | |
| SCHEMBL860157 | 0.75 | KCNH2 (0.58) | TLR8KCNH2LMNACYP1A2GPBAR1 | |
| SCHEMBL915012 | 0.75 | ABCB11 (0.50) | TLR8KCNH2KDM4EABCB11LMNA | |
| SCHEMBL797638 | 0.74 | KCNH2 (0.61) | TLR8KCNH2LMNACYP1A2GPBAR1 | |
| SCHEMBL5367040 | 0.74 | KCNH2 (0.61) | TLR8KCNH2LMNACYP1A2GPBAR1 | |
| SCHEMBL3347670 | 0.74 | L3MBTL1 (0.61) | TLR8KCNH2ABCB11LMNACYP1A2 | |
| SCHEMBL2514450 | 0.74 | KCNH2 (0.61) | TLR8KCNH2LMNACYP1A2GPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9981916-B2 | Pyridazine derivatives as RORc modulators | GENENTECH, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| EP-3066082-B1 | 5,6,7,8-TETRAHYDRO-5,8-METHANOCINNOLINE DERIVATIVES AS RORC MODULATORS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | HOFFMANN LA ROCHE (CH) | 2017-12-20 | — | — | EP | disclosed |
| EP-3066082-A1 | 5,6,7,8-TETRAHYDRO-5,8-METHANOCINNOLINE DERIVATIVES AS RORC MODULATORS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | F. Hoffmann-La Roche AG (CH) | 2016-09-14 | — | — | EP | disclosed |
| WO-2015067575-A1 | 5,6,7,8-TETRAHYDRO-5,8-METHANOCINNOLINE DERIVATIVES AS RORC MODULATORS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-05-14 | — | — | WO | disclosed |
| US-20150126491-A1 | PYRIDAZINE DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2015-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126491-A1 | PYRIDAZINE DERIVATIVES AS RORc MODULATORS | RORC, RORB, RORA | TLR8 799/4885KCNH2 1386/4885KDM4E 2727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.